Foghorn Therapeutics (FHTX) Current Leases: 2020-2025
Historic Current Leases for Foghorn Therapeutics (FHTX) over the last 5 years, with Sep 2025 value amounting to $6.8 million.
- Foghorn Therapeutics' Current Leases fell 22.98% to $6.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.8 million, marking a year-over-year decrease of 22.98%. This contributed to the annual value of $9.1 million for FY2024, which is 6.45% up from last year.
- Per Foghorn Therapeutics' latest filing, its Current Leases stood at $6.8 million for Q3 2025, which was up 9.38% from $6.2 million recorded in Q2 2025.
- In the past 5 years, Foghorn Therapeutics' Current Leases ranged from a high of $9.1 million in Q1 2025 and a low of $5.7 million during Q2 2022.
- In the last 3 years, Foghorn Therapeutics' Current Leases had a median value of $8.5 million in 2023 and averaged $8.0 million.
- Its Current Leases has fluctuated over the past 5 years, first skyrocketed by 7,582.42% in 2021, then tumbled by 31.88% in 2025.
- Foghorn Therapeutics' Current Leases (Quarterly) stood at $7.0 million in 2021, then fell by 14.64% to $6.0 million in 2022, then soared by 42.68% to $8.5 million in 2023, then increased by 6.45% to $9.1 million in 2024, then decreased by 22.98% to $6.8 million in 2025.
- Its Current Leases stands at $6.8 million for Q3 2025, versus $6.2 million for Q2 2025 and $9.1 million for Q1 2025.